Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (3805)	2/4/2000 7:33:00 AM
From: Joe	Read Replies (1) \| Respond to of 4140

Important News Sunrise Technologies Names Alan H. Magazine, Ph.D. to Board of Directors FREMONT, Calif.--(BW HealthWire)--Feb. 4, 2000--Sunrise Technologies International, Inc. (Nasdaq:SNRS) today announced that it has named Alan H. Magazine, Ph.D., as a member of its Board of Directors. Magazine currently advises companies and organizations on management and governmental matters. He most recently served as president of the Health Industry Manufacturers Association (HIMA) in Washington D.C. from 1990-1999. HIMA is the largest association of medical technology companies in the world, representing more than 800 companies. Prior to joining HIMA, Magazine served as president of the Council on Competitiveness in Washington D.C. from 1986-1990 which is a private, non-profit organization comprised of business, labor and academic leaders that works to increase U.S. competitiveness in the world marketplace. Magazine earned a Ph.D. from the University of Maryland. "We are very pleased Alan joined our Board of Directors. His vast experience in the medical technology field, his familiarity with the regulatory processes around the world, and his understanding of the domestic and international marketplaces will add great value to our Board and our Company," said C. Russell Trenary III, president & CEO for Sunrise Technologies International, Inc. "The addition of Alan to our Board brings us a skilled administrator with vast experience in Washington, D.C. and will prove to be a valuable asset for our Board of Directors," said Joseph Koenig, chairman of the Sunrise Board of Directors. "The potential of this Company is exactly the type of exciting and dynamic opportunity with which I wanted to be involved. I am very proud to join the Sunrise Board of Directors," stated Magazine. The Sunrise Hyperion LTK System was recently recommended for approval by the FDA Ophthalmic Devices Advisory Panel for the treatment of hyperopia from +.75 to +2.50 diopters with conditions. In addition, the Company announced last week it has been awarded recommendation for ISO 9001 and EN 46001 certification, an essential element for competing in world markets. Sunrise Technologies International, Inc., is a Fremont company that produces and markets high technology products revolutionizing treatment methods in eye care. The Company develops Holmium laser-based systems, which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. These Systems(1) incorporate a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural again), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in clinical trials in the United States. Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgment, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements. (1) Caution-Investigational Device: Federal law restricts this device to investigational use in the U.S. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com. CONTACT: Sunrise Technologies International Susan Lorigan, 510/623-9001 (Investor Relations) Ed Coghlan, 510/771-2399 (Investor Relations)